Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.

Sandborn, William J; Feagan, Brian G; Marano, Colleen; Zhang, Hongyan; Strauss, Richard; Johanns, Jewel; Adedokun, Omoniyi J; Guzzo, Cynthia; Colombel, Jean-Frederic; Reinisch, Walter; Gibson, Peter R; Collins, Judith; Järnerot, Gunnar; Rutgeerts, Paul

Sandborn, William J; Feagan, Brian G; Marano, Colleen; Zhang, Hongyan; Strauss, Richard; Johanns, Jewel; Adedokun, Omoniyi J; Guzzo, Cynthia; Colombel, Jean-Frederic; Reinisch, Walter; Gibson, Peter R; Collins, Judith; Järnerot, Gunnar; Rutgeerts, Paul.

Afiliação

Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, California. Electronic address: wsandborn@ucsd.edu.
Feagan BG; Robarts Research Institute, University of Western Ontario, London, Ontario, Canada.
Marano C; Janssen Research and Development, LLC, Spring House, Pennsylvania.
Zhang H; Janssen Research and Development, LLC, Spring House, Pennsylvania.
Strauss R; Janssen Research and Development, LLC, Spring House, Pennsylvania.
Johanns J; Janssen Research and Development, LLC, Spring House, Pennsylvania.
Adedokun OJ; Janssen Research and Development, LLC, Spring House, Pennsylvania.
Guzzo C; Janssen Services, LLC, Horsham, Pennsylvania.
Colombel JF; Department of Hepatogastroenterology and Centre d'Investigation Clinique Centre Hospitalier Universitaire de Lille, Université Lille Nord de France, Lille, France; Icahn School of Medicine at Mount Sinai, New York, New York.
Reinisch W; Department of Gastroenterology and Hepatology, Universitätsklinik für Innere Medizin III, Vienna, Austria.
Gibson PR; Department of Gastroenterology, Monash University, Alfred Hospital, Melbourne, Victoria, Australia.
Collins J; Division of Gastroenterology, Department of Medicine, Oregon Health Sciences University, Portland, Oregon.
Järnerot G; Division of Gastroenterology, Department of Medicine, Örebro University Hospital, Örebro, Sweden.
Rutgeerts P; Department of Gastroenterology, University Hospital, Gasthuisberg, Leuven, Belgium.

Gastroenterology ; 146(1): 96-109.e1, 2014 Jan.

Article em En | MEDLINE | ID: mdl-23770005

Assuntos

Anti-Inflamatórios/uso terapêutico; Anticorpos Monoclonais/uso terapêutico; Colite Ulcerativa/tratamento farmacológico; Imunossupressores/uso terapêutico; Fator de Necrose Tumoral alfa/antagonistas & inibidores; Corticosteroides/uso terapêutico; Adulto; Ácidos Aminossalicílicos/uso terapêutico; Método Duplo-Cego; Quimioterapia Combinada; Feminino; Humanos; Injeções Subcutâneas; Quimioterapia de Manutenção/métodos; Masculino; Mercaptopurina/uso terapêutico; Metotrexato/uso terapêutico; Pessoa de Meia-Idade; Índice de Gravidade de Doença; Resultado do Tratamento

Palavras-chave

Fully Human Monoclonal Antibody; IV; Inflammatory Bowel Disease; NNT; PURSUIT; PURSUIT-M; Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment; Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment Maintenance; Randomized Withdrawal Trial; SC; TNFα; UC; intravenous; number needed to treat; subcutaneous; tumor necrosis factor-α; ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite Ulcerativa / Fator de Necrose Tumoral alfa / Imunossupressores / Anti-Inflamatórios / Anticorpos Monoclonais Tipo de estudo: Clinical_trials Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Gastroenterology Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google